How Long Does Akathisia Last and What Affects It?

Akathisia can last anywhere from a few days to several years, depending almost entirely on which type you have, what triggered it, and how quickly the cause is addressed. Acute akathisia, the most common form, typically starts within days to weeks of beginning or increasing a medication and often resolves within days to weeks once the offending drug is reduced, switched, or stopped. Tardive akathisia tells a very different story: in one study of patients who discontinued the triggering medication, symptoms persisted for an average of nearly three years, with some cases lasting seven years or longer.¹ The gap between those two timelines is enormous, and understanding what determines where you fall on that spectrum is the practical question most people are really asking.

The Four Types and Their Timelines

Clinicians classify akathisia into four categories based on when it appears relative to drug treatment: acute, tardive, withdrawal, and chronic.² These are not just academic labels. Each one carries a different expected timeline, and knowing which type you are dealing with shapes what to expect.

Acute akathisia shows up within the first few days to weeks of starting a new medication or raising the dose. It is by far the most frequently encountered form, and it tends to improve relatively quickly when the triggering medication is lowered or changed. Many people see relief within days of a dose adjustment, though the exact speed depends on how the drug clears the body and what replacement strategy is used.

Tardive akathisia develops after months or even years of continuous treatment with drugs that block dopamine receptors. The word “tardive” signals late onset, and this form is far more stubborn. In a study that followed 26 patients who were able to stop their dopamine-blocking medications, akathisia persisted for a mean of 2.7 years, with a range stretching from a few months to seven years.¹ Some patients never fully recovered during the follow-up period.

Withdrawal akathisia appears shortly after a dopamine-blocking drug is stopped or its dose is suddenly cut. It can feel identical to acute akathisia, but the timing is the clue: it follows discontinuation rather than initiation. This form is usually self-limiting, fading over weeks as the brain readjusts, though the exact timeline varies.

Chronic akathisia is a catch-all for cases that simply do not resolve, regardless of whether the original trigger has been removed. Risk factors for developing chronic or tardive forms are poorly understood, though older age, female sex, iron deficiency, negative symptoms in schizophrenia, cognitive problems, and a diagnosis of an affective disorder have all been flagged as areas needing further study.³

Which Medications Trigger It

Antipsychotic drugs are the most common cause. Akathisia is fundamentally a syndrome of motor restlessness tied to medications that block dopamine receptors in the brain, and it is characterized by an inner sense of unease combined with a physical urge to keep moving.⁴ Both older (first-generation) and newer (second-generation) antipsychotics can cause it, though rates differ between individual drugs. A case report documented marked akathisia from aripiprazole, a widely prescribed second-generation antipsychotic, with motor symptoms resolving completely within four weeks after the drug was withdrawn and a short course of clonazepam was started.⁵ That four-week resolution is relatively fast, and it illustrates how acute cases can clear up promptly when the drug is identified and stopped.

Antipsychotics are not the only culprits. Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), have been linked to akathisia and other movement-related side effects. A review of published case reports found that SSRIs accounted for roughly 80% of antidepressant-associated cases of movement disorders, including akathisia.⁶ Anti-nausea drugs like metoclopramide and prochlorperazine, which also block dopamine receptors, are another underappreciated source. Even some recreational substances can trigger the condition: a case study documented akathisia developing after chronic use of synthetic cathinones, which powerfully alter dopamine signaling.⁷

The type of drug matters for duration because it shapes how easy or hard it is to stop. If akathisia comes from a short course of an anti-nausea drug in the emergency room, the exposure is brief and the symptoms are likely to resolve quickly. If it comes from an antipsychotic being used to manage schizophrenia, discontinuing the drug may not be a simple option, which means the akathisia can persist as long as the medication continues.

Why Some People Are More Vulnerable

Not everyone on the same drug at the same dose develops akathisia. The reasons are partly pharmacological and partly genetic. At the pharmacological level, the risk rises with the degree of dopamine receptor blockade in the brain. Research on antipsychotic dosing has found that when dopamine D2 receptor occupancy in a key brain region exceeds roughly 80%, the likelihood of movement-related side effects, including akathisia, climbs substantially.⁸ This means higher doses, faster dose escalation, and drugs with tighter receptor binding all push the odds up.

The genetic piece centers on how quickly your body breaks down medications. Enzymes in the liver, part of the CYP450 family, metabolize most psychiatric drugs. People who carry certain gene variants produce less efficient versions of these enzymes, which means drug levels in their blood climb higher than expected for a given dose. Research has found that people who developed akathisia had higher rates of these diminished-function CYP450 variants compared to the general primary-care population.⁹ When these genetic vulnerabilities combine with other drugs that compete for the same enzymes, metabolism slows even further and the effective dose in the body can spike well beyond what was prescribed.¹⁰

This matters for duration because if the root cause is a drug that your body cannot clear efficiently, simply waiting for it to wash out after stopping takes longer than it would for someone with typical metabolism. It also means that dose reductions may need to be more aggressive for slow metabolizers to bring relief.

What the Brain Is Doing During Akathisia

The dominant theory holds that akathisia results from disrupted dopamine signaling, particularly in brain circuits that govern movement and reward. When a drug blocks dopamine receptors, compensatory changes kick in: the noradrenergic (adrenaline-related) system ramps up, and serotonin pathways may also shift. A review of the literature proposed that the ideal treatment for akathisia should both restore dopamine signaling in the affected areas and counteract the compensatory noradrenergic surge.¹¹ This dual disruption helps explain why the condition feels so distinctly awful: it is not simply about muscle twitches or fidgeting. The subjective experience is one of profound inner restlessness and mental distress that drives the physical movement, rather than the other way around.

Brain imaging has started to show what this looks like in real time. In the aripiprazole case mentioned earlier, PET scanning revealed abnormally high metabolic activity in both sides of the putamen, a brain region involved in movement planning. After the drug was stopped and symptoms resolved, that hypermetabolism presumably settled down.⁵ Findings like this remain preliminary, but they offer a biological snapshot of what acute akathisia looks like at the level of brain metabolism. A lack of consensus on the full neurobiology is part of why treatment can still feel like trial and error.¹²

Treatments That Can Shorten or Relieve It

The single most effective strategy for shortening akathisia is dealing with the trigger. If a medication caused it, lowering the dose, switching to a drug with a lower risk profile, or stopping the drug entirely (when clinically safe) is the first move. Guidelines for managing antipsychotic-induced akathisia support dose reduction, switching antipsychotics, and adding specific adjunct medications.¹³ But for many people, especially those who need the antipsychotic for an underlying psychiatric condition, simply stopping the drug is not realistic. That is where add-on treatments come in.

A 2024 systematic review and network meta-analysis pooled data from 15 trials and found that six medications outperformed placebo for treating antipsychotic-induced akathisia: mirtazapine, biperiden, vitamin B6, trazodone, mianserin, and propranolol.¹⁴ Mirtazapine showed the largest effect, followed by biperiden and vitamin B6. By contrast, cyproheptadine, clonazepam, zolmitriptan, and valproate did not show significant effects compared to placebo in the same analysis.

Propranolol, a beta-blocker, has the longest track record. An older controlled trial found that both propranolol and benztropine significantly improved akathisia within three to five days of treatment, while placebo had no meaningful effect.¹⁵ That three-to-five-day window is important because it gives a rough benchmark for how quickly you can expect to feel improvement with targeted treatment, at least for acute cases. Earlier literature had noted that anticholinergic drugs like benztropine only partially relieve akathisia, with beta-blockers, benzodiazepines, and clonidine serving as alternatives.¹⁶

For practical purposes, propranolol and mirtazapine currently have the strongest evidence base.¹⁷ Vitamin B6 is intriguing because it is available over the counter and well-tolerated, though the evidence supporting it comes from small trials. Other agents like gabapentin and pregabalin have been explored in preliminary reports but lack robust evidence so far.

Why It Gets Misdiagnosed and Why That Extends Suffering

One of the cruelest aspects of akathisia is how often it goes unrecognized. A person pacing, fidgeting, and expressing intense distress can easily be mistaken for someone whose underlying psychiatric condition is worsening. When that happens, the typical clinical response is to increase the dose of the very medication causing the problem, which makes the akathisia worse. This diagnostic confusion is well-documented: prompt and accurate detection remains difficult, and there is no consensus on the full neurobiology of the condition.¹²

Structured rating tools exist to help. The Barnes Akathisia Rating Scale, first published in 1989 and later revisited, grades observable restless movements, the person’s subjective awareness of restlessness, and the distress it causes, along with a global severity score.¹⁸ The scale also includes criteria for pseudoakathisia, a variant where the restless movements are present but the person does not report the characteristic inner sense of needing to move. In one study, roughly a fifth of inpatients had pseudoakathisia, which complicates assessment further.

The practical takeaway: if you or someone you know develops new restlessness after starting or changing a psychiatric medication, raise the possibility of akathisia directly with the prescriber. The sooner it is correctly identified, the sooner the dose can be adjusted and an add-on treatment started, and the shorter the episode is likely to be.

The Psychological Toll of Prolonged Akathisia

Duration is not just about physical discomfort. Akathisia causes considerable distress in a group of patients who are already psychiatrically vulnerable.¹⁹ The inner restlessness has been described by patients as one of the most unbearable side effects they have ever experienced, worse than many of the psychiatric symptoms the medication was prescribed to treat.

The relationship between akathisia and suicidal behavior has been debated for decades. A systematic review of the evidence found that two of four studies showed a weak correlation between antipsychotic-related akathisia and suicidal behavior, while the other two did not support the link. The reviewers concluded that, based on existing evidence, akathisia cannot be reliably linked to suicidal behavior, though proactive screening in this vulnerable group is advisable.²⁰ A separate study found a more nuanced picture: akathisia was associated with suicidality in men but not women, and with agitation in people who had never taken antipsychotics before and depression in those who had prior exposure.²¹

What is not debated is that the longer akathisia lasts, the greater its impact on quality of life, medication adherence, and trust in treatment. People who suffer through weeks or months of unrecognized akathisia are understandably reluctant to try psychiatric medications again, which can derail treatment for the condition that brought them to a prescriber in the first place.

When Akathisia Signals Something Else

Persistent akathisia that does not respond to dose changes or add-on treatments sometimes turns out to be an early warning sign of another movement disorder. A report on two relatively young psychiatric patients found that akathisia appearing at the start of antipsychotic therapy and persisting despite dose reductions preceded the early onset of tardive dyskinesia, a separate and often more disabling condition involving involuntary movements of the face and limbs.²² This does not mean that everyone with stubborn akathisia will develop tardive dyskinesia, but it does mean that akathisia that refuses to budge warrants close follow-up and reassessment rather than passive waiting.

The term akathisia itself predates modern psychiatric medication by decades. It was coined in 1901 by the Czech neurologist Ladislav Haskovec to describe a phenomenon he observed in patients who had no exposure to any of the drugs now associated with the condition.²³ Akathisia can occasionally arise in contexts beyond medication, including neurological diseases like Parkinson’s and, in some case reports, after brain injury, though the evidence base for non-drug causes remains thin.²⁴ When akathisia appears without an obvious drug trigger, a broader neurological workup becomes important.

Iron Deficiency and Other Modifiable Factors

Among the risk factors flagged for chronic and tardive akathisia, iron deficiency stands out because it is both measurable and treatable. Iron plays a role in dopamine synthesis and regulation, and low iron stores in the brain could plausibly amplify the dopamine disruption that drives akathisia. The epidemiological literature has specifically named iron deficiency as a factor warranting further investigation in the development of persistent forms of the condition.³ Some clinicians now check serum ferritin levels in patients with treatment-resistant akathisia, though this practice is not yet universal.

Other modifiable factors that can influence how long akathisia lasts include polypharmacy (taking multiple drugs that interact with the same metabolic pathways), caffeine intake (which can worsen restlessness), and the speed of dose changes. Rapid dose escalation is a well-known risk factor for triggering akathisia, and gradual titration is one of the simplest preventive strategies available. Similarly, abruptly stopping a dopamine-blocking drug rather than tapering it can provoke withdrawal akathisia, which might have been avoided with a slower discontinuation schedule.

1
PubMed. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials
2
PubMed. Managing antipsychotic-induced acute and chronic akathisia
3
Oxford Academic. The Epidemiology of Drug-induced Akathisia: Part II. Chronic, Tardive, and Withdrawal Akathisias
4
PubMed. The Barnes Akathisia Rating Scale–revisited
5
International Clinical Psychopharmacology. Aripiprazole‑induced akathisia associated with bilateral putaminal hypermetabolism on PET
6
PubMed. Extrapyramidal Reactions Associated with Serotonergic Antidepressants
7
PubMed Central. Akathisia after chronic usage of synthetic cathinones: A case study
8
Cambridge University Press. Antipsychotic efficacy: Relationship to optimal D2-receptor occupancy
9
PubMed Central. Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family
10
PubMed. The relevance of cytochrome P450 polymorphism in forensic medicine and akathisia-related violence and suicide
11
PubMed Central. Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment
12
PubMed Central. Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges.
13
PubMed Central. The Assessment and Treatment of Antipsychotic-Induced Akathisia
14
PubMed Central. Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-Analysis
15
PubMed. A controlled comparison of the effects of propranolol, benztropine, and placebo on akathisia: an interim analysis
16
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. Treatment of Acute Neuroleptic‐Induced Movement Disorders
17
PubMed Central. Struggling to find Effective Pharmacologic Options for Akathisia? B-CALM!
18
The British Journal of Psychiatry. A Rating Scale for Drug-Induced Akathisia
19
PubMed. A critical review of akathisia, and its possible association with suicidal behaviour
20
PubMed Central. The Relationship Between Antipsychotic-Induced Akathisia and Suicidal Behaviour: A Systematic Review
21
Acta Neuropsychiatrica. Akathisia and atypical antipsychotics: relation to suicidality, agitation and depression in a clinical trial
22
PubMed Central. Persistent akathisia associated with early tardive dyskinesia
23
The British Journal of Psychiatry. Ladislav Haskovec and akathisia: 100th anniversary
24
PubMed Central. Mild Traumatic Brain Injury as a Risk Factor for Parkinsonism, Tics, and Akathisia: A Systematic Review and Meta-Analysis